Seeking to stem its own opioid crisis, the Canadian government announced plans to restrict marketing of the addictive painkillers by the pharmaceutical industry to physicians.
Among the steps the health ministry envisions is requiring drug makers to develop and implement risk management plans, which would mean that companies would have to obtain clearance for materials provided to doctors in order to ensure advertising complies with marketing authorization.
About the Author Reprints
